PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report)’s stock price traded up 1.5% on Thursday . The company traded as high as $1.80 and last traded at $1.66. 11,569 shares traded hands during trading, an increase of 31% from the average session volume of 8,831 shares. The stock had previously closed at $1.63.
PharmaCyte Biotech Price Performance
The company’s 50-day simple moving average is $1.69 and its 200-day simple moving average is $1.80.
About PharmaCyte Biotech
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
Featured Articles
- Five stocks we like better than PharmaCyte Biotech
- ESG Stocks, What Investors Should Know
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Consumer Staples Stocks, Explained
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- What Are Some of the Best Large-Cap Stocks to Buy?
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
